under the scanner

Competition Commission of India pulls up Roche for anti-competitive practices

In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities.

The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair business practices. Roche has been found, prima facie, of misusing its dominant status to keep competition out for its breast cancer medicine Trastuzumab.

In July 2016, Mylan Pharmaceuticals and Biocon Limited had approached the Competition Commission of India alleging that Roche was indulging in anti-competitive practices to protect its monopoly on the drug. The commission has asked its director general of investigation to conduct an enquiry and submit a report in 60 days.

The complaint alleged that Roche, the second largest pharmaceutical company in the world by revenue, tried to influence regulatory authorities, indulged in anti-competitive activities such as raising unwarranted concerns regarding the safety and efficacy of biosimilars – biological products that are almost identical to another but manufactured by a different company and clinically no different in terms of safety and effectiveness. The complaint also alleged that Roche influenced regulatory standards and tender conditions and abused the legal process to stall approval and marketing of biosimilars.

Roche’s Trastuzumab is a biological drug made from cells of living organisms or their products. Biocon’s drug is a biosimilar. Roche had allegedly approached hospitals and doctors and raised questions about efficacy of biosimilars.

“Roche’s campaign against biosimilars, priced much lower than its own drug and therefore more accessible and affordable, is infamous,” said Kalyani Menon-Sen, Coordinator for Campaign for Affordable Trastuzumab. “There is a nexus between doctors and pharma companies.”

According to Menon-Sen, women getting treatment from private hospitals report that they are pressurised to use only Roche’s drug provided at the hospital. If they insist on purchasing the drug from outside at a cheaper price, or ask for the biosimilar, they are either refused treatment or are warned that the hospital will not be answerable for any adverse consequences.

The Competition Commission of India has made a similar observation. Referring to an ongoing Delhi High Court case in which Roche has challenged approval of Biocon’s product, the commission noted that Biocon has valid approval from the Drugs Controller General of India. The commission has stated that: “The practices adopted by Roche Group to create an impression about the propriety of the approvals granted, the safety and efficacy of biosimilars, the risk associated and the outcome of the on-going court proceedings in the medical fraternity, including doctors, hospitals, tender authorities, institutes etc… prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the market.”

“Women seeking treatment are at their most vulnerable and they will go by what the doctor says, regardless of the costs,” said Menon- Sen. There is no scientific basis for the claim that the biosimilar is less effective than the Roche version.”

In an email reply to Scroll.in, a Biocon spokesperson said, “We welcome the decision of the Competition Commission of India. A fair and ethical competitive environment will enable access to affordable life-saving therapies to larger patient pools with unmet needs.”

The order cited example of misinformation by Roche to promote its product. On April 25, 2016 a single bench of the Delhi High Court ordered in favour of Roche in the civil suit against approval of Biocon’s biosimilar. However, three days later, the division bench reinstated the position prior to April 25 allowing Biocon’s biosimilar in the market. On some occasions, Roche used the earlier order to make its case. For example, in a letter dated June 3, 2016, written to the store officer of the All India Institute of Medical Sciences Roche cited the April 25, 2016 decision without revealing the later order.

Biocon, the developer of biosimilar, and Mylan, which is responsible for its marketing, are not the only companies who seem to be affected by Roche’s campaign. The Competition Commission of India’s 36-page order also notes that the Swiss giant has used legal pathways to delay entry of other biosimilars. Reliance Life Science’s biosimilar version of Trastuzumab under the brand name TrastuRel was approved for manufacturing and marketing in June 2015. However the drug could be launched only in May 2016 due to a legal suit filed against it by Roche in the Delhi high Court. Cadila Healthcare sought an injunction from the Bombay High Court before the launching its biosimilar Vivitra to pre-empt any action by Roche.

Punitive action

If the Competition Commission of India finds Roche’s conduct anti-competition, the company might have to pay a penalty.

“If Roche has indeed tried to influence hospitals, doctors and regulatory authorities regarding safety of Biocon’s product in the manner alleged, then it might be a serious breach of the Competition Act,” said Kabir Dixit, an advocate at the Supreme Court of India who regularly advises on competition law.

Referring to the commission’s broad powers to remedy any abuse of dominant position, Dixit said: “From directing the enterprise to discontinue the abuse to imposing penalty commensurate with the sort of benefits derived on account of such abuse. Penalties can be up to 10% of the average turnover for the last three preceding financial years. [The commission] even has the power to direct division of an enterprise enjoying dominant position.”

A spokesperson of Roche said, “We are reviewing the order and cannot comment at this point.”

Effect on patients

According to a 2016 study by the Indian Council of Medical Research, breast cancer is the most common cancer India. With 1.5 lakh new cases registered in 2016, breast cancer accounted for 10% of all cancer cases.

If treated early, the survival rate of breast cancer is as high as 89% as in developed countries, according to data from cancer registries in the United States.

However, in India, treatment is still out of reach for a majority of patients. Roche’s Trastuzumab was sold at Rs 1,20,000 for 440 mg from the year 2002 to 2012 . A course of 12 injections costs anywhere between Rs 6 lakh to Rs 8 lakh. In 2013, Roche launched a cheaper version of the same drug at Rs 75,000. In 2013, Biocon too launched its biosimilar at Rs 57,500. Subsequently Roche also brought down its price to the same level.

“Even though MRP remains the same, after negotiations with the company, the same drug is available at Rs 33,000,” said Menon-Sen. “This price is also unaffordable. All companies have to work towards reducing the prices even further down.”

She pointed out that even through the Competition Commission of India’s order is landmark in itself, the problem lies in the regulation of price in India, or rather the lack of it. “If it is left to the companies, we will never have decent pricing,” she said. “If the priority is public health, then the government has to set a price ceiling that makes the drug affordable to all.”

We welcome your comments at letters@scroll.in.
Sponsored Content BY 

Relying on the power of habits to solve India’s mammoth sanitation problem

Adopting three simple habits can help maximise the benefits of existing sanitation infrastructure.

India’s sanitation problem is well documented – the country was recently declared as having the highest number of people living without basic sanitation facilities. Sanitation encompasses all conditions relating to public health - especially sewage disposal and access to clean drinking water. Due to associated losses in productivity caused by sickness, increased healthcare costs and increased mortality, India recorded a loss of 5.2% of its GDP to poor sanitation in 2015. As tremendous as the economic losses are, the on-ground, human consequences of poor sanitation are grim - about one in 10 deaths, according to the World Bank.

Poor sanitation contributes to about 10% of the world’s disease burden and is linked to even those diseases that may not present any correlation at first. For example, while lack of nutrition is a direct cause of anaemia, poor sanitation can contribute to the problem by causing intestinal diseases which prevent people from absorbing nutrition from their food. In fact, a study found a correlation between improved sanitation and reduced prevalence of anaemia in 14 Indian states. Diarrhoeal diseases, the most well-known consequence of poor sanitation, are the third largest cause of child mortality in India. They are also linked to undernutrition and stunting in children - 38% of Indian children exhibit stunted growth. Improved sanitation can also help reduce prevalence of neglected tropical diseases (NTDs). Though not a cause of high mortality rate, NTDs impair physical and cognitive development, contribute to mother and child illness and death and affect overall productivity. NTDs caused by parasitic worms - such as hookworms, whipworms etc. - infect millions every year and spread through open defecation. Improving toilet access and access to clean drinking water can significantly boost disease control programmes for diarrhoea, NTDs and other correlated conditions.

Unfortunately, with about 732 million people who have no access to toilets, India currently accounts for more than half of the world population that defecates in the open. India also accounts for the largest rural population living without access to clean water. Only 16% of India’s rural population is currently served by piped water.

However, there is cause for optimism. In the three years of Swachh Bharat Abhiyan, the country’s sanitation coverage has risen from 39% to 65% and eight states and Union Territories have been declared open defecation free. But lasting change cannot be ensured by the proliferation of sanitation infrastructure alone. Ensuring the usage of toilets is as important as building them, more so due to the cultural preference for open defecation in rural India.

According to the World Bank, hygiene promotion is essential to realise the potential of infrastructure investments in sanitation. Behavioural intervention is most successful when it targets few behaviours with the most potential for impact. An area of public health where behavioural training has made an impact is WASH - water, sanitation and hygiene - a key issue of UN Sustainable Development Goal 6. Compliance to WASH practices has the potential to reduce illness and death, poverty and improve overall socio-economic development. The UN has even marked observance days for each - World Water Day for water (22 March), World Toilet Day for sanitation (19 November) and Global Handwashing Day for hygiene (15 October).

At its simplest, the benefits of WASH can be availed through three simple habits that safeguard against disease - washing hands before eating, drinking clean water and using a clean toilet. Handwashing and use of toilets are some of the most important behavioural interventions that keep diarrhoeal diseases from spreading, while clean drinking water is essential to prevent water-borne diseases and adverse health effects of toxic contaminants. In India, Hindustan Unilever Limited launched the Swachh Aadat Swachh Bharat initiative, a WASH behaviour change programme, to complement the Swachh Bharat Abhiyan. Through its on-ground behaviour change model, SASB seeks to promote the three basic WASH habits to create long-lasting personal hygiene compliance among the populations it serves.

This touching film made as a part of SASB’s awareness campaign shows how lack of knowledge of basic hygiene practices means children miss out on developmental milestones due to preventable diseases.


SASB created the Swachhata curriculum, a textbook to encourage adoption of personal hygiene among school going children. It makes use of conceptual learning to teach primary school students about cleanliness, germs and clean habits in an engaging manner. Swachh Basti is an extensive urban outreach programme for sensitising urban slum residents about WASH habits through demos, skits and etc. in partnership with key local stakeholders such as doctors, anganwadi workers and support groups. In Ghatkopar, Mumbai, HUL built the first-of-its-kind Suvidha Centre - an urban water, hygiene and sanitation community centre. It provides toilets, handwashing and shower facilities, safe drinking water and state-of-the-art laundry operations at an affordable cost to about 1,500 residents of the area.

HUL’s factory workers also act as Swachhata Doots, or messengers of change who teach the three habits of WASH in their own villages. This mobile-led rural behaviour change communication model also provides a volunteering opportunity to those who are busy but wish to make a difference. A toolkit especially designed for this purpose helps volunteers approach, explain and teach people in their immediate vicinity - their drivers, cooks, domestic helps etc. - about the three simple habits for better hygiene. This helps cast the net of awareness wider as regular interaction is conducive to habit formation. To learn more about their volunteering programme, click here. To learn more about the Swachh Aadat Swachh Bharat initiative, click here.

This article was produced by the Scroll marketing team on behalf of Hindustan Unilever and not by the Scroll editorial team.